Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT3789 + pembrolizumab in SMARCA4-mutant solid tumors
NCT06682806Phase 2Terminated
- Sponsor
- Prelude Therapeutics
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of PRT3789 in esophageal cancer and non-small cell lung cancer (NSCLC), sponsored by Prelude Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 2 years, Adverse Events at 2 years and 2 more. Started Jun 2025; status: terminated.
02
Drugs
PRT3789
03
Conditions
esophageal cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06682806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682806.